Anti–PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised Phase 3 trial. Lancet. 2017;390(10089):29–39. doi:10.1016/S0140-6736(17)30565-2
   PubMed Web of Science ®Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–125. doi:10.1056/NEJMoa1713137
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135. doi:10.1056/NEJMoa1504627
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. doi:10.1056/NEJMoa1606774
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–265. doi:10.1016/S0140-6736(16)32517-X
   PubMed Web of Science ®Google Scholar
• Nosaki K, Saka H, Hosomi Y, et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer. 2019;135:188–195. doi:10.1016/j.lungcan.2019.07.004
   PubMed Web of Science ®Google Scholar
• Duma N, Abdel-Ghani A, Yadav S, et al. Sex differences in tolerability to anti-programmed cell death protein 1 therapy in patients with metastatic melanoma and non-small cell lung cancer: are we all equal? Oncologist. 2019;24(11):e1148–e1155. doi:10.1634/theoncologist.2019-0094
   PubMed Web of Science ®Google Scholar
• Arias Ron D, Areses Manrique MC, Mosquera Martínez J, et al. Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: a subgroup analysis of the Galician lung cancer group. J Geriatr Oncol. 2020. doi:10.1016/j.jgo.2020.11.010
   PubMed Web of Science ®Google Scholar
• Nicholson AG, Chansky K, Crowley J, et al. The international association for the study of lung cancer lung cancer staging project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(3):300–311. doi:10.1016/j.jtho.2015.10.008
   PubMed Web of Science ®Google Scholar
• Schwartz LH, Litière S, de Vries E, et al. RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–137. doi:10.1016/j.ejca.2016.03.081
   PubMed Web of Science ®Google Scholar
• Li L, Li G, Rao B, et al. Landscape of immune checkpoint inhibitor-related adverse events in Chinese population. Sci Rep. 2020;10(1):15567. doi:10.1038/s41598-020-72649-5
   PubMed Web of Science ®Google Scholar
• Shankar B, Zhang J, Naqash AR, et al. Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer. JAMA oncol. 2020;6(12):1952–1956. doi:10.1001/jamaoncol.2020.5012
   PubMed Web of Science ®Google Scholar
• Nishijima TF, Muss HB, Shachar SS, Moschos SJ. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis. Cancer Treat Rev. 2016;45:30–37. doi:10.1016/j.ctrv.2016.02.006
   PubMed Web of Science ®Google Scholar
• Elias R, Giobbie-Hurder A, McCleary NJ, Ott P, Hodi FS, Rahma O. Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. J Immunother Cancer. 2018;6(1):26. doi:10.1186/s40425-018-0336-8
   PubMed Web of Science ®Google Scholar
• Wu Y, Ju Q, Qian B, Zhang F, Shi H. The effectiveness of PD-1 inhibitors in non-small cell lung cancer (NSCLC) patients of different ages. Oncotarget. 2018;9(8):7942–7948. doi:10.18632/oncotarget.23678
   PubMedGoogle Scholar
• Elkrief A, Richard C, Malo J, et al. Efficacy of immune checkpoint inhibitors in older patients with non-small cell lung cancer: real-world data from multicentric cohorts in Canada and France. J Geriatr Oncol. 2020;11(5):802–806. doi:10.1016/j.jgo.2020.01.002
   PubMed Web of Science ®Google Scholar
• Corbaux P, Maillet D, Boespflug A, et al. Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting. Eur J Cancer. 2019;121:192–201. doi:10.1016/j.ejca.2019.08.027
   PubMed Web of Science ®Google Scholar
• Lichtenstein MRL, Nipp RD, Muzikansky A, et al. Impact of age on outcomes with immunotherapy in patients with non-small cell lung cancer. J Thorac Oncol. 2019;14(3):547–552. doi:10.1016/j.jtho.2018.11.011
   PubMed Web of Science ®Google Scholar
• Katsura H, Suga Y, Araya T, et al. Efficacy and safety of nivolumab in patients with advanced non-small-cell lung cancer and poor performance status. J Cancer. 2019;10(10):2139–2144. doi:10.7150/jca.31217
   PubMed Web of Science ®Google Scholar
• Naqash AR, Ricciuti B, Owen DH, et al. Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. Cancer Immunol Immunother. 2020;69(7):1177–1187. doi:10.1007/s00262-020-02536-5
   PubMed Web of Science ®Google Scholar
• Dall’Olio FG, Maggio I, Massucci M, Mollica V, Fragomeno B, Ardizzoni A. ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-a systematic review and meta-analysis of real world data. Lung Cancer. 2020;145:95–104. doi:10.1016/j.lungcan.2020.04.027
   PubMed Web of Science ®Google Scholar
• Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17(12):e542–e551). doi:10.1016/S1470-2045(16)30406-5
   PubMed Web of Science ®Google Scholar
• Sacher AG, Gandhi L. Biomarkers for the clinical use of PD-1/PD-L1 inhibitors in non-small-cell lung cancer: a review. JAMA oncol. 2016;2(9):1217–1222. doi:10.1001/jamaoncol.2016.0639
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537–546. doi:10.1200/JCO.18.00149
   PubMed Web of Science ®Google Scholar
• Jodai T, Saruwatari K, Ikeda T, et al. Clinical outcomes and predictive value of programmed cell death-ligand 1 expression in response to anti-programmed cell death 1/ligand 1 antibodies in non-small cell lung cancer patients with performance status 2 or greater. Int J Clin Oncol. 2021;26(1):78–86. doi:10.1007/s10147-020-01789-5
   PubMed Web of Science ®Google Scholar